Human Herpesvirus-8 (HHV-8)-negative/idiopathic multicentric Castleman disease (iMCD) is a poorly understood disease involving polyclonal lymphoproliferation with dysmorphic germinal centers, constitutional symptoms, and multi-organ failure. Patients can experience thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly, and normal immunoglobulin levels, -iMCD-TAFRO. Others experience thrombocytosis, milder effusions, and hypergammaglobulinemia, -iMCD-Not Otherwise Specified (iMCD-NOS). Though the etiology is unknown in both subtypes, iMCD symptoms and disease progression are believed to be driven by a cytokine storm, often including interleukin-6 (IL-6). However, approximately two-thirds of patients do not respond to anti-IL-6 therapy; alternative drivers and signaling pathways are not known for anti-IL-6 nonresponders. To identify potential mediators of iMCD pathogenesis, we quantified 1129 proteins in 13 plasma samples from six iMCD patients during flare and remission. The acute phase reactant NPS-PLA2 was the only significantly increased protein (P 5 .017); chemokines and complement were significantly enriched pathways. Chemokines represented the greatest proportion of upregulated cytokines, suggesting that iMCD involves a chemokine storm. The chemokine CXCL13, which is essential in homing B cells to germinal centers, was the most upregulated cytokine across all patients (log2 fold-change 5 3.22). Expression of CXCL13 was also significantly increased in iMCD lymph node germinal centers compared to controls in a stromal meshwork pattern. We observed distinct proteomic profiles between the two iMCD-TAFRO patients, who both failed anti-IL-6-therapy, and the four iMCD-NOS patients, in whom all three treated with anti-IL-6-therapy responded, suggesting that differing mechanisms may exist. This study reveals proteomic differences between flare and remission and the potential to molecularly define iMCD subgroups. and one sample during remission (defined as CRP < 10 mg/L and less than two minor diagnostic criteria 5 ) were collected from each patient.
signaling pathways, dysregulated cell types, and composition of the cytokine storm, including the various families of cytokines, such as interleukins and chemokines, are not known in iMCD. Chemokines regulate leukocyte migration, lymphoid tissue organization, innate and adaptive immunity, angiogenesis, and immune system development, whereas interleukins are often involved in stimulating immune responses, such as inflammation.
Several lines of evidence suggest that excess interleukin-6 (IL-6), a cytokine that promotes B cell and plasma cell growth, plays an important role in symptoms and disease progression in many iMCD patients. 11, 12 Anti-IL-6 monoclonal antibodies (mAb) tocilizumab (anti-IL-6 receptor) and siltuximab (anti-IL-6) have been approved for iMCD in various regions of the world. 5, 13, 14 However, approximately twothirds of iMCD patients did not respond to IL-6 blockade with siltuximab in the registrational trial, 14 and, of the 35 siltuximab nonresponders in the study, more than one-half had normal IL-6 levels during active disease (<5 pg/mL). 12 In agreement, a recent study of serum cytokines found that more than one-half of the 17 iMCD patients examined had undetectable IL-6 levels during flare. 15 These results suggest that IL-6 independent pathways may be driving disease pathogenesis in a portion of iMCD patients. Current treatment options for these patients include corticosteroids, rituximab, and cytotoxic chemotherapies, which have limited efficacy and significant toxicity in iMCD. 16 Efforts to identify new treatment strategies for patients who do not respond to anti-IL-6 therapy are limited by a poor understanding of iMCD pathogenesis.
Here, we performed for the first time unbiased, systematic quantification of plasma proteins in six iMCD patients' matched flare and remission samples using SomaLogic SOMAscan® to generate insights into iMCD pathogenesis.
| M E TH ODS

| Patients and sample collection
All patients consented to the research, which was approved by the University of Arkansas for Medical Sciences Institutional Review Board.
Clinical data were collected as part of routine care. Between 2007 and 2016, peripheral blood samples were collected from six patients whose diagnoses are consistent with the iMCD diagnostic criteria. 5 One sample during flare (defined as C-Reactive Protein (CRP) > 10 mg/L and the presence of at least two iMCD-related minor diagnostic criteria 5 ) and one sample during remission (defined as CRP < 10 mg/L and less than two minor diagnostic criteria 5 ) were collected from each patient.
An additional sample was collected for patient 6 during a subsequent flare, which occurred three years after the first flare. In total, 13 samples collected from six iMCD patients were analyzed.
The demographic and disease characteristics of the six iMCD patients are presented in Supporting Information Table S1 . Median age at diagnosis was 44.5 years, similar to previous reports. 16 One patient is female (16.7% Table S3 ). This analysis identified 14 significant KEGG gene-sets; cytokine-cytokine receptor interaction, chemokine signaling pathway, and complement and coagulation cascades were the top 3 gene-sets by combined score. To address the possibility that the set of 1129 proteins quantified through SOMAscan® was itself enriched for cytokine and chemokine pathways, we compared the results to the background set of all SOMAscan® proteins quantified. Chemokine signaling pathway and complement and coagulation cascades remained significantly enriched (P 5 .03 and P 5 .04, respectively), and the P value for cytokine-cytokine receptor interaction was .09 (Supporting Information Table S4 ), which confirmed enrichment of these pathways among the most upregulated proteins. We repeated gene-set analyses using the Reactome database.
Gene-sets enriched at least 2-fold relative to the background set of all SOMAscan® proteins included cytokine signaling, such as G-protein coupled receptors and IL-1, 24, 210, and 213 signaling, chemokine signaling, and the complement cascade (Supporting Information Table S5 ).
Results from both databases are consistent with involvement of cytokine and chemokine signaling and complement activation in iMCD flare.
| Chemokines are the most upregulated family of cytokines during iMCD flare
Given the enrichment of cytokine signaling and the generally accepted model of iMCD as a cytokine storm, 23 we performed additional analyses to investigate which cytokines were most elevated. Of the 120 cytokines measured by the SOMAscan® platform the average fold-change of chemokines was significantly higher than interleukins (P 5 .048) and other cytokines (P 5 .025) ( Figure 2A , Supporting Information Table S6 ).
Chemokines represented six of the eight cytokines that exceeded 2-fold upregulation. Further, nearly one-half of the quantified chemokines (43.6%) were represented among the top quartile, which was significantly greater than interleukins (11.1%, P 5 .006) or other cytokines (18.5%, P 5 .008). The three chemokines that were most upregulated during flare were CXCL13 (or B Lymphocyte Chemoattractant (BLC)), CCL23 (or Myeloid Progenitor Inhibitory Factor 1-1 (MPIF-1)), and CCL21 (or 6CKine). In contrast to the increased abundance of chemokines, relatively few interleukins were upregulated during iMCD flare.
IL-6 was the most upregulated interleukin on average. However, this result is confounded by patients receiving anti-IL-6-therapy, which is known to increase circulating IL-6 levels. 24 The highest flare IL-6 level was found in the only patient (patient 5) who was receiving anti-IL-6-therapy during the flare draw, and the highest remission IL-6 levels were found in the patients on anti-IL-6-therapy. Given the potential bias of anti-IL-6 therapy, we removed samples obtained during anti-IL-6-therapy and calculated a log2-fold-change for each of the remaining flare samples (patients 1, 2, 3, 4, 6 (flare 2)) relative to the average of the remaining remission samples (patients 4, 6). Patients 1 and 2 had greater than 3-fold increased IL-6, while patients 3, 4, and 6 had less than 50%
change. These results suggest that the cytokine storm observed in iMCD includes significant upregulation of chemokines.
| CXCL13 expression is elevated in iMCD lymph node tissue
To identify a potential cellular source of the elevated circulating CXCL13, we performed immunohistochemistry on iMCD lymph Table S7 ). Further, we performed a LIMMA modeling analysis on all proteins for iMCD-TAFRO and iMCD-NOS subgroups and plotted the results. Though no proteins reached statistical significance in the iMCD-NOS subgroup, 229 proteins were statistically significant after adjustment in the iMCD-TAFRO subgroup (Supporting Information Figure S1 ). These results demonstrate clear differences in proteomic profiles between groups of iMCD patients. However, it is unclear if this distinction is due to clinical subtypes and/or anti-IL-6 response.
| PI3K/Akt/mTOR identified as a potential targetable pathway in iMCD
To generate insights into potential signaling pathways, we performed gene-set and pathway analyses on the proteins with >2-fold-change separately for iMCD-TAFRO and iMCD-NOS groups (listing of proteins in Supporting Information Tables S8 and S9 ). To ensure that our results
were not a product of enrichment among the 1129 analytes that were quantified, we compared results to the background of all SOMAscan® proteins. IPA ranked "Phosphoinositide 3-kinase (PI3K) signaling in B lymphocytes" in the top two canonical pathways for both clinical subgroups by P value. All of the top five ranked pathways for iMCD-TAFRO and iMCD-NOS were significant by P < .001 (Supporting Information Table S10 ). When KEGG gene-set analyses were performed on 
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the iMCD-TAFRO cases, MAPK signaling and chemokine signaling were significantly enriched compared to background proteins (P 5 .02
and P 5 .02). PI3K-Akt was 1.22-fold enriched and had the third highest combined score, but did not meet significance when compared to background proteins (P 5 .16) (Supporting Information Table S11 ). For iMCD-NOS cases, KEGG gene-set analyses identified chemokine signaling and Vascular Endothelial Growth Factor (VEGF) signaling among the top five gene-sets, which were also significantly enriched over background (all P < .01) (Supporting Information Table S12 ). Lastly, we performed an enrichment analysis for compounds in the LINCS 1000 database that decrease gene expression of proteins with > 2-fold upregulation during flare among iMCD-TAFRO and iMCD-NOS cases.
After multiple comparison adjustment, six of the 20 most significant compounds (highest combined score) identified to downregulate protein expression for iMCD-TAFRO patients were dual PI3K/mechanistic target of rapamycin (mTOR) inhibitors or PI3K inhibitors. The remaining 14 compounds each had different targets (Table 1 ). For iMCD-NOS patients, no compounds were identified below the false discovery rate to downregulate protein expression of the >2-fold upregulated proteins. The identification of the PI3K/Akt/mTOR pathway across analyses performed on four separate gene-set databases suggest that it may be a novel therapeutic target for treating iMCD.
| D ISC USSION
Here, we have systematically characterized in a small patient cohort the breadth of soluble protein changes during iMCD flare in peripheral blood. Our results support the general model that iMCD flares involve a cytokine storm and acute inflammation. Acute phase reactants contributed strongly to the altered proteomic profile of patients in flare.
NPS-PLA2, the only protein to meet statistical significance across all samples, has been found to be elevated in malignancies and inflammatory disorders and highly correlated with other inflammatory markers, including CRP and SAA. [25] [26] [27] [28] While iMCD has been described as an IL-6-driven lymphoproliferative disorder, 29 recent findings suggest that IL-6 is not the driving cytokine in all cases, and >50% of patients with iMCD do not respond to anti-IL6-therapy. 14 Our findings further indicate that iMCD pathogenesis is more complex than previously described. In our cohort, anti-IL-6-therapy induced a complete response in three of five patients in whom it was administered. However, the flare IL-6 levels were not highly upregulated compared to paired remission samples in these patients.
When the anti-IL-6 treated samples were removed, we found that the degree of fold-change may have been underestimated. It is also possible that some patients may have dysregulation in IL-6 signaling such that small changes in IL-6 levels result in major downstream effects. 30 We previously found a significantly increased frequency of an IL-6 receptor polymorphism among iMCD patients (49%) compared to controls (33%). Individuals with this polymorphism expressed significantly higher levels of soluble IL-6 receptor, which we hypothesized could contribute to increased IL-6 activity through trans-signaling. 31 A major finding in this study is that chemokines are significantly upregulated compared to interleukins and other cytokines during iMCD flare. These data suggest that the 'cytokine storm' described in iMCD would be more appropriately considered a 'chemokine storm.'
The most upregulated circulating cytokine is the chemokine CXCL13, which is essential for lymph node development and B cell homing to germinal centers; upregulated levels of CXCL13 have been observed in disorders that overlap clinically and histopathologically with iMCD. [32] [33] [34] [35] [36] This finding is also notable given that two flare samples were collected from patients (patient 2 and 6, flare 1) while on rituximab, which has been shown to decrease serum CXCL13 levels and may have dampened CXCL13 fold-change between flare and remission. [37] [38] [39] CXCL13 levels were still more than 4-fold higher in flare compared to remission in those patients. Additionally, no patients received rituximab within 12 months of remission sample collection, so decreased remission sample CXCL13 is not expected. Thus, CXCL13
may have been further upregulated across patients if rituximab had not been administered during two patients' flare samples.
Consistent with proteomic data, we found increased germinal center CXCL13 staining in a diffuse, meshwork pattern in iMCD patients' Proteins upregulated > 2-fold during iMCD-TAFRO flare were analyzed using the LINCS 1000 database. Six of the top 20 compounds identified to downregulate the upregulated proteins are of the PI3K & mTOR inhibitor class.
lymph node tissue compared with metastasis-free sentinel lymph nodes from breast cancer patients. Lymph node tissue from all six iMCD patients was collected at the time of diagnosis prior to any treatment administration, and therefore the observed CXCL13 is representative of the treatment-naive state of iMCD flare. CXCL13 is primarily secreted by FDCs and Tfh cells to home B cells into lymph node germinal centers (via CXCR5). 40 Diffuse, strong expression of CXCL13 on
FDCs has been described in lymph node tissue from unicentric Castleman disease and HHV-8-positive MCD. 41 FDC prominence is frequently observed in iMCD, 5 and FDC dysplasia has been occasionally reported. [41] [42] [43] [44] [45] Similar to what is observed in iMCD, increased numbers of lymphoid follicles are seen in CXCL13 overexpressing mice. 32, 46 However, the germinal centers in iMCD are typically small with few B cells and atrophic features, which is observed in CXCL13 knock-out mice. Overlap between the phenotype observed in these mice and the histopathological hallmarks of iMCD 47 suggest that there may be dysregulation of CXCL13 signaling in iMCD. Perhaps elevated CXCL13
secreted by FDCs could drive B cell maturation into plasma cells, which are increased in iMCD lymph nodes, 5 and could lead to auto-antibody producing plasma cells. Alternatively, the increased CXCL13 could represent increased, nonspecific germinal center activity, 40 which has been observed in related disorders, [32] [33] [34] [35] [36] Unexpectedly, we saw strong increases in the abundance of complement proteins during iMCD flares. Increases in complement factors have not been previously described in iMCD. C3b, the main effector molecule of the complement system, and its cleavage products C3a
and C3a-des-arginine were among the most upregulated proteins in the iMCD-TAFRO cases. Auto-antibodies, which are present in approximately 30% of iMCD cases, can trigger complement activation when bound to self-antigen. 16 Future studies are required to determine complement's role in iMCD pathogenesis and will be an important area to explore given there is already a safe and effective anti-complement antibody in clinical use. in iMCD-NOS. VEGF-A (VEGF-121) was greater than two-fold upregulated on average across all patients in our study. Elevated VEGF-A, which promotes cell survival, angiogenesis, and vascular permeability, has been previously described in iMCD, 16, 49 and patients often demonstrate VEGF-related symptoms, such as highly vascularized lymph nodes, eruptive cherry hemangiomatosis, 50 and vascular leak syndrome. 5 Interestingly, IL-6 was not significantly increased in either the iMCD-TAFRO or iMCD-NOS groups compared to healthy controls in the Iwaki study. Iwaki et al. also found that platelet-derived growth factor subunit A (PDGF-AA), which is released upon platelet activation, 15, 51 was the only cytokine significantly lower in iMCD-TAFRO compared with controls. There was also a trend toward decreased PDGF-AA in iMCD-TAFRO compared to iMCD-NOS (P 5 .09).
15
PDGF-AA was likewise > 2-fold downregulated in iMCD-TAFRO and >2-fold upregulated in iMCD-NOS in our study. PDGF-AA has been found to be elevated in immune/idiopathic thrombocytopenic purpura (ITP), in whom the thrombocytopenia is caused by peripheral thrombocyte consumption. 52 The etiology of the thrombocytopenia in iMCD-TAFRO is not known. Though iMCD-TAFRO and ITP share similar clinical features, including thrombocytopenia and megakaryocyte hyperplasia, the divergent PDGF-AA levels suggest that there may be different mechanisms involved in the thrombocytopenia in these disorders. 15 Despite differences in assays, sample types, and comparison groups, there were several consistent findings between these studies, such as significant differences between iMCD-TAFRO and iMCD-NOS.
We observed striking differences between patient proteomes from the two groups that associated with iMCD-TAFRO and iMCD-NOS. In our study, these groups also associated with response to anti-IL6-therapy. Notably, over 200 proteins were significantly upregulated or downregulated after adjustment in the iMCD-TAFRO group, which would be expected considering the high correlation between patients, while no proteins in the iMCD-NOS group met significance. Both iMCD-TAFRO patients were anti-IL-6 nonresponders and all three iMCD-NOS patients treated with anti-IL-6-therapy responded. Importantly, there have been reports of iMCD-TAFRO cases that have responded to anti-IL-6-therapy [53] [54] [55] [56] [57] [58] [59] and others that have not. 50, [60] [61] [62] [63] [64] [65] [66] The proteomic differences between the two groups may represent differences between clinical subtypes or be a signature of anti-IL-6
response. In either case, the most upregulated proteins and enriched signaling pathways may constitute therapeutic targets.
PI3K, a key member of the PI3K/Akt/mTOR signaling pathway, was identified as a top canonical pathway in both subgroups, and six inhibitors of PI3K/Akt/mTOR signaling were identified in the top twenty compounds predicted to downregulate expression of upregulated proteins in iMCD-TAFRO patients. PI3K/Akt/mTOR is a key regulator of angiogenesis, lymphoproliferation, and inflammation that is therapeutically targetable. Results suggesting involvement of the PI3K/ Akt/mTOR pathway were consistently significant across the different pathway and gene-set databases, strengthening our finding that the PI3K/Akt/mTOR signaling pathway may be a rational treatment target for anti-IL-6 nonresponders.
A major limitation of this study is the small number of patient samples analyzed. Though our decision to include only iMCD patients with matched flare and remission samples limited the number of eligible patients with this rare disease, we wanted to identify proteomic changes that can be attributed to disease state and therapies. We expect that the continued growth of the international, multi-center Castleman Disease Collaborative Network, 67 which was started in 2012, will be instrumental in recruitment of larger numbers of patients with this rare disease for future translational studies. Furthermore, while large-scale plasma protein profiling gives a systematic view of protein changes, this approach may overlook highly potent proteins where small changes in concentration result in major biological effects as well as nonsecreted factors, which were not assayed. Given the exploratory nature of the analysis, there is also the potential for false discovery. Therefore, we employed a false discovery rate and performed gene-set enrichment analyses to improve our power for identifying significantly enriched or depleted groups of genes. Another limitation of this study is that renal dysfunction affects excretion of circulating proteins, particularly small (<25 kDa) proteins, 68 and three patients (2, 5, 6) experienced borderline or elevated creatinine suggestive of renal dysfunction during flare. Decreased excretion may therefore have contributed to increased concentration of some proteins, though these increased proteins may also contribute to iMCD pathophysiology. Further, treatments, such as anti-IL-6 therapies (siltuximab and tocilizumab), rituximab, corticosteroids, and chemotherapies may affect the plasma proteome. We addressed the potential effects of anti-IL-6 therapy and rituximab and provided each of the treatments administered to these patients. None of the major observations in this study segregated to only patients on rituximab, corticosteroids, or chemotherapies, and other than those discussed, we are not aware of any specific effects of these agents on the noted proteins. Lastly, the lack of samples from a healthy control population prevent comparison of disease state from both flare and remission with otherwise healthy controls. However, we sought to identify proteomic changes occurring within individuals between flare and remission. Comparisons between iMCD flare samples and healthy controls can introduce inter-individual differences in plasma proteomes that can make changes difficult to interpret.
Despite these limitations our study provides insights into the pathogenesis of iMCD, including identification of a 'chemokine storm' associated with iMCD flares and potential involvement of lymph node stromal cells. Additionally, our studies reveal the proteomic differences between flare and remission and the potential to molecularly define iMCD subgroups. Future studies testing the contribution of individual disease mediators will be critical to building a better understanding of iMCD and leading the field to better treatments. 
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